The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Modern medicines series SGLT2 Inhibitors: Webinar 2 - SGLT2 inhibitors and the heart

Modern medicines series SGLT2 Inhibitors: Webinar 2 - SGLT2 inhibitors and the heart

Publication date: Wednesday, 24 February 2021
Contributor(s): Cliff Bailey, Martin Hadley-Brown

Professor Cliff Bailey and Dr Martin Hadley-Brown discuss the effects of SGLT2 inhibitors on cardiovascular function and their role in the management of CV disease, specifically: Cardiovascular disease in type 2 diabetes; SGLT2 inhibitors lower blood pressure; SGLT2 inhibitors reduced heart failure risk; Mechanisms of SGLT2 inhibitors on heart and circulation; Improve BP control independently of other antihypertensives; Reduce risk of new onset or worsening heart failure; May benefit atherosclerotic cardiovascular disease; Positioned in algorithms for type 2 diabetes by CV effects.

Download the factsheet to this webinar below or watch the on-demand video here:
View the on-demand webinar

And don't forget to complete the CPD programme on our Sister site BJPCN to get your CPD points and download your certificate: 
Go to the CPD programme*

This webinar is supported by Boehringer Ingelheim through an unrestricted educational grant.


*Please note that registration is required to complete the CPD module. Simply register to create your free-of-charge personal account
 

Sponsorship information:
This webinar is supported by Boehringer Ingelheim through an unrestricted educational grant
Topics covered:
Category: Webinars
Edition: Volume 1 Number 2 February 2021
Contributor(s): Cliff Bailey, Martin Hadley-Brown

Article search and filter